Last reviewed · How we verify
Rexulti
At a glance
| Generic name | Rexulti |
|---|---|
| Also known as | Brexpiprazole |
| Sponsor | University of Chicago |
| Target | 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| Annual revenue | 1400 |
Approved indications
- Major depressive disorder
- Schizophrenia
Common side effects
- Weight increased
- Akathisia
- Headache
- Somnolence
- Insomnia
- Nasopharyngitis
- Restlessness
Key clinical trials
- Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D) (PHASE4)
- Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia (PHASE1)
- Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (PHASE3)
- Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole) (PHASE1)
- The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia. (PHASE1)
- National Pregnancy Registry for Psychiatric Medications
- Precision Care for Major Depressive Disorder (PHASE4)
- Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |